Prospective Grant of an Exclusive Patent License: Antibody-Based Therapy for the Treatment of CD20 Expressing Lymphomas
| Published date | 22 May 2020 |
| Citation | 85 FR 31193 |
| Record Number | 2020-11036 |
| Section | Notices |
| Court | National Institutes Of Health |
Federal Register, Volume 85 Issue 100 (Friday, May 22, 2020)
[Federal Register Volume 85, Number 100 (Friday, May 22, 2020)]
[Notices]
[Page 31193]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-11036]
[[Page 31193]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Antibody-Based
Therapy for the Treatment of CD20 Expressing Lymphomas
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Heart, Lung, and Blood Institute, an institute of
the National Institutes of Health, Department of Health and Human
Services, is contemplating the grant of an exclusive patent license to
practice the inventions embodied in the Patents and Patent Applications
listed in the Supplementary Information section of this notice to
Retargeted Therapeutics, a corporation incorporated under the laws of
the state of Delaware.
DATES: Only written comments and/or applications for a license which
are received by the National Heart, Lung, and Blood on or before June
8, 2020 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated an exclusive patent license
should be directed to: Vidita Choudhry, Ph.D. Technology Transfer
Manager, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479,
phone number (301)-594-4095, or [email protected].
SUPPLEMENTARY INFORMATION:
Intellectual Property
--------------------------------------------------------------------------------------------------------------------------------------------------------
Issued patent
NIH ref No. Title Patent application No. Filing date No. Issue date
--------------------------------------------------------------------------------------------------------------------------------------------------------
E-758-2013-0-US-01............... Antibody Targeting 61/924,967................ January 8, 2014.......... .............. .........................
Cell Surface
Deposited
Complement Protein
C3d and Use
Thereof.
E-758-2013-1-PCT-01.............. Antibody Targeting PCT/US2015/010620......... January 8, 2015.......... .............. .........................
Cell Surface
Deposited
Complement Protein
C3d and Use
Thereof.
E-758-2013-1-US-02............... Antibody Targeting 15/110,577................ July 8, 2016............. 10,035,848 July 31, 2018.
Cell Surface
Deposited
Complement Protein
C3d and Use
Thereof.
E-758-2013--1-CA-03.............. Antibody Targeting 2936346................... January 8, 2015.......... ..............
Cell Surface
Deposited
Complement Protein
C3d and Use
Thereof.
E-758-2013-1-EP-04............... Antibody Targeting 15701442.4................ January 8, 2015.......... 3092252 September 18, 2019.
Cell Surface
Deposited
Complement Protein
C3d and Use
Thereof.
E-758-2013-1-US-05............... Antibody Targeting 16/047,929................ July 27, 2018............ ..............
Cell Surface
Deposited
Complement Protein
C3d and Use
Thereof.
E-025-2019-0-US-01............... Antibody Targeting 62/945,569................ December 9, 2019......... .............. .........................
Cell Surface
Deposited
Complement Protein
C3d and Use
Thereof.
--------------------------------------------------------------------------------------------------------------------------------------------------------
Intellectual property listed here includes all U.S. and foreign
patents and applications claiming priority to any member of the
aforementioned applications.
The patent rights in these inventions have been assigned or
exclusively licensed to the Government of the United States of America.
The prospective exclusive license territory may be worldwide and in
fields of use that may be limited to use of anti-C3d monoclonal
antibodies (mAbs) to potentiate anti-tumor activity of anti-CD20 mAbs
for the treatment of B-cell lymphomas.
The aforementioned Patents and Patent applications cover technology
directed to development of anti-C3d antibody or antibody fragments to
re-target cells that have escaped from existing mAbs therapy and to
potentiate the anti-tumor activity of therapeutic mAbs and eliminate
antigen loss variants.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing.
The prospective exclusive license may be granted unless within fifteen
(15) days from the date of this published notice, the National Heart,
Lung, and Blood Institute receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: May 14, 2020.
Bruce D. Goldstein,
Director, Office of Technology Transfer and Development, National
Heart, Lung, and Blood Institute.
[FR Doc. 2020-11036 Filed 5-21-20; 8:45 am]
BILLING CODE 4140-01-P
